Abstract-Hypoglycemia or low blood glucose is dangerous and can result in unconsciousness, seizures and even death. It is a common and serious side effect of insulin therapy in patients with diabetes. HypoMon is a non-invasive monitor that measures some physiological parameters continuously to provide detection of hypoglycemic episodes in Type 1 diabetes mellitus patients (T1DM). Based on heart rate and corrected QT interval of the ECG signal, we have continued to develop Bayesian neural network detection algorithms to recognize the presence of hypoglycemic episodes. From a clinical study of 16 children with T1DM, natural occurrence of nocturnal hypoglycemic episodes are associated with increased heart rates (1.033±0.242 vs. 1.082±0.298, P<0.06) and increased corrected QT intervals (1.031±0.086 vs. 1.060±0.084, P<0.001). The overall data were organized into a training set (8 patients) and a test set (another 8 patients) randomly selected. Using the optimal Bayesian neural network with 10 hidden nodes which was derived from the training set with the highest log evidence, the sensitivity (true positive) value for detection of hypoglycemia in the test set is 89.2%.
I. INTRODUCTION
ESULTS of the Diabetes Control and Complications Trial (DCCT) Research Group in 1993 [1] showed that intensive insulin therapy for a mean of six years (maintaining glycemic levels to a target HbA 1c level of 7%) as opposed to conventional therapy (with resultant mean HbA 1c level of 9%) significantly lowered the risk for retinopathy by 47%, nephropathy by 54% and for neuropathy by 60% [1] [2] .
However, episodes of hypoglycemia, especially at night, were common among people treated for T1DM, largely because usual insulin preparations do not adequately mimic the normal patterns of endogenous insulin secretion [2] . In the DDCT, patients assigned to intensive therapy experienced a threefold increase incidence of severe hypoglycemic episodes over those receiving conventional therapy [1, 3] . In that report, severe hypoglycemic episodes are defined as those in which the patient required assistance to treat the event and had documented blood glucose levels Manuscript received April 6, 2008 less than 50 mg/dl (2.8 mmol/l). Thus hypoglycemia proved to be a limiting factor in achieving improved diabetes control.
Symptoms of hypoglycemia arise from the activation of the autonomous central nervous systems (autonomic symptoms) and from reduced cerebral glucose consumption (neuroglycopenic symptoms), some of the latter being potentially life threatening. Autonomic symptoms (e.g., tachycardia, palpitations, shakiness, sweating) are activated before neuroglycopenic symptoms (e.g., reduced concentration, blurred vision, dizziness). Autonomic symptoms may provide the initial indication of the presence of hypoglycemia and allow the patient to recognise and correct the ensuing episode [6] .
Nocturnal hypoglycemia is particularly dangerous because sleep reduces and may obscure autonomic counterregulatory responses, so that an initially mild episode may become severe. The risk of severe hypoglycemia is high at night, with at least 50% of all severe episodes occurring during that time [7] . Deficient glucose counter-regulation may also lead to severe hypoglycemia even with modest insulin elevations.
Recently, we have developed an optimal Bayesian neural network algorithm for the detection of hypoglycaemic episodes in T1DM children using physiological parameters. Using the data from 25 children with T1DM volunteered for the 4-hour glucose clamp study to provide 28 sets of physiological responses, we have found that hypoglycemic episodes in T1DM children can be detected non-invasively and continuously [8] [9] .
In this paper, instead of performing 4-hour glucose clamp studies, we aim to explore the effects of natural occurrence of nocturnal hypoglycemic episodes on physiological responses. Section II provides an overview of the method used for non-invasive and continuous detection of hypoglycemia. Section III presents the development and results of an optimal Bayesian neural network used for the identification of nocturnal hypoglycemic episodes in T1DM children. Section IV provides a conclusion for this study.
II. METHODS

A. Non-Invasive Hypoglycemia Monitor
There are some non-invasive blood glucose monitoring systems currently available but each has specific drawbacks in terms of functioning, cost, reliability and obtrusiveness. Recently, GlucoWatch G2 Biographer from Cygnus Inc was designed to measure glucose levels up to 3 times per hour for 12 hours. The AutoSensor (the disposable component) which was attached to the back of the GlucoWatch monitor and adhered to the skin will provide 12 hours of measurement. The product used reverse iontophoresis to extract and measure glucose levels non-invasively using interstitial fluid. It had to be calibrated before each measurement period and required a two-hour warm-up period. It required costly disposable components, the gel pads must be replaced after each use, sweating might cause skipped readings, and the measurement had a time delay of about 10-15 minutes. As a result of these limitations this device is no longer available. Intensive research has been devoted to the development of hypoglycaemia alarms, exploiting principles that range from detecting changes in skin conductance (due to sweating) to measurements, by glucose sensors, of subcutaneous tissue glucose concentrations (Pickup, 2000; Rebrin; 1999). However, none of these have proved sufficiently reliable or unobtrusive.
Although real-time continuous glucose monitoring systems (CGMS) are now available to give real-time estimations of glucose levels, these still lack the sensitivity to be used as alarms. For the MiniMed Medtronic (Northridge, CA) CGMS, the median error was reported as 10-15% at a plasma glucose of 4-10 mmol/l [10] [11] [12] and the low efficacy of CGMS (79.1% sensitivity) in detecting unrecognised hypoglycaemia has been confirmed [13] . For the Abbott Freestyle Navigator CGMS, the sensor accuracy was lowest during hypoglycaemia (3.9 mmol/l), with the median absolute relative difference (ARD) reported as 26.4% [14] . As these are median values, the errors may be significantly greater and, as a result, the manufacturers do not recommend their use as an alarm.
We have developed a continuous non-invasive hypoglycemia monitor which uses physiological responses [8] [9] . HypoMon® (Hypoglycemia Monitor) from AIMedics Pty Ltd (Fig. 1) is a non-invasive monitor that measures physiological parameters continuously to provide detection of hypoglycemic episodes in Type 1 diabetes mellitus patients (T1DM). The system consists of a battery-powered chest belt worn that houses a set of four skin-surface biosensor electrodes for the measurement of physiological parameters and a hand-held receiver computer. The sensors are composed of a conductive polymer-based material such as polypyrrole which has low impedance and low noise characteristics. These characteristics enable the sensors to measure both skin impedance and quality ECG signals. The chest belt digitizes, encrypts and transmits the measured parameters to the receiver computer which analyzes and identifies hypoglycemic episodes. An alarm system is available for warning various stages of hypoglycemia.
B. Bayesian Neural Network
Bayesian neural networks were firstly introduced by MacKay as a practical and powerful means to improve the generalization of neural networks [20] [21] [22] [23] . Bayesian learning of multi-layer perceptron neural networks is performed by considering Gaussian probability distributions of the weights which can give the best generalization [20] [21] . In particular, the weights w in network X are adjusted to their most probable values given the training data D . Specifically, the posterior distribution of the weights can be computed using Bayes' rule as follows
where ( ) Regularization can be used to prevent any weights becoming excessively large, which can lead to poor generalization. For a multi-layer perceptron neural network classifier with G groups of weights and biases, a weight decay penalty term proportional to the sum of squares of the weights and biases is added to the data error function D E to obtain the cost function
where S is called the cost function, g ξ is a non-negative scalar, sometimes knows as a hyperparameter, ensuring the distribution of weights and biases in group g and g w is the vector of weights and biases in group g . In network training, the hyperparameters are initialized to be arbitrary small values. The cost function is then minimized using an advanced optimization technique. When the cost function has reached a local minimum, the hyperparameter g
) must be re-estimated. This task requires computing the Hessian matrix of the cost function:
where H is the Hessian matrix of D E and g I is the identity matrix, which selects weights in the g th group. The number of 'well-determined' weights g γ in group g is calculated based on the old value of g ξ as follows [15] ( )
The hyperparameters need to be re-estimated several times until the cost function value ceases to change significantly between consecutive re-estimation periods. After the network training is completed, the values of parameters g γ and g ξ are then used to compute the log evidence of network i X having M hidden nodes as follows [22] [23] 
where g W is the number of weights and biases in group g , and Ω is set to be 3 10 [23] . However, Ω is a minor factor because it is the same for all models and therefore does not effect to the relative comparison of log evidence of different network architectures. The above Eq. (5) is used to compare different networks having different numbers of hidden nodes. The best network will be selected with the highest log evidence.
C. Study
Sixteen children with T1DM (14.6±1.5 years) volunteered for the 10-hour overnight hypoglycemia study at the Princess Margaret Hospital for Children in Perth, Australia. Each patient was monitored overnight for the natural occurrence of nocturnal hypoglycemia. Data were collected with approval from Women's and Children's Health Service, Department of Health, Government of Western Australia, and with informed consent.
A comprehensive patient information and consent form was formulated and approved by the Ethics Committee. The consent form included the actual consent and a revocation of consent page. Each patient received this information consent form at least two weeks prior to the start of the studies. He/she had the opportunity to raise questions and concerns with any medical advisers, researchers and the investigators. For the children participating in this study, the parent or guardian signed the relevant forms. HypoMon was used to measure the required physiological parameters, while the actual blood glucose (BG) levels were collected as reference using Yellow Spring Instruments. The main parameters used for the detection of hypoglycemia are the heart rate, corrected QT interval and skin impedance. The actual blood glucose profiles for 16 T1DM children are shown in Fig. 2 .
III. RESULTS
The responses from 16 T1DM children exhibit significant changes during the hypoglycemia phase against the non-hypoglycemia phase. Normalization was used to reduce patient-to-patient variability and to enable group comparison by dividing the patient's heart rate, corrected QT interval and skin impedance by his/her corresponding values at time zero. The study shows that associated with hypoglycemic episodes in 16 T1DM children, using normalized values, their heart rates increase (1.082±0.298 vs. 1.033±0.242, P<0.06) and their corrected QT intervals increase significantly (1.060±0.084 vs. 1.031±0.086, P<0.001). However, in this clinical study (natural occurrence), the reduction of skin impedances of the patients were not strong (1.111±1.460 vs. 1.108±1.277, P<0.984). It should be noted that in our previous 4-hour glucose clamp study [8] [9] , skin impedances reduced significantly during hypoglycemic episodes.
The detection of hypoglycemic episodes (BG<=60 mg/dl) using these variables is based on an optimal Bayesian neural network algorithm developed from the obtained clinical data. This neural network has a multilayer feed-forward neural network structure with one hidden node layer and one output node layer. In effect, it estimates the presence of hypoglycemia at sampling period k based on the basis of the data at sampling period k and the previous data at sampling period k-1. In general, the sampling period is 5 minutes and approximately 30 data points are used for each patient. The overall data set consisted of a training set and a test set, each with 8 patients randomly selected. For these, the whole data set which included both hypoglycemia data part and non-hypoglycemia data part were used. For optimal robustness of the evaluation, we applied the evidence framework for Bayesian inference to the training set and found the feed forward neural network architecture with 10 hidden nodes yielded the highest evidence as shown in Fig.  3 . The final feed-forward multi-layer neural network had heart rate, corrected QT interval and skin impedance as inputs, 10 hidden nodes and 1 output node (estimated blood glucose level). From the optimal neural network which was derived from the training set with the highest log evidence, the sensitivity (true positive) value for detection of hypoglycemia in the test set is 89.2%.
IV. CONCLUSION
The above result indicates that hypoglycemic episodes in T1DM children can be detected non-invasively and continuously effectively from the real-time physiological responses measured by HypoMon. It is noted that the relevant physiological parameters (QTc interval, heart rate and skin impedance) are less correlated to the actual blood glucose levels when the patients experienced hypoglycemic episodes through natural occurrence against the situation when clamp studies were performed. It can be seen that during clamp studies, the relevant physiological responses are well controlled whereas during the natural occurrence of hypoglycemic episodes, the overall physiological responses are less predictable.
